P16-5 (EPS with Complex Capital Structure) Amy Dyken, controller at Fitzgerald Pharmaceutical Indus- tries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgeralds financial statements. Below is selected financial information for the fiscal year ended June 30, 2014.

FITZGERALD PHARMACEUTICAL INDUSTRIES

SELECTED BALANCE SHEET

INFORMATION

JUNE 30, 2014

Long-term debt Notes payable, 10% $ 1,000,000

8% convertible bonds payable $ 5,000,000

10% bonds payable $ 6,000,000

Total long-term debt $12,000,000

Shareholders equity Preferred stock, 6% cumulative, $50 par value,

100,000 shares authorized, 25,000 shares issued and outstanding $ 1,250,000

Common stock, $1 par, 10,000,000 shares authorized, 1,000,000 shares issued and outstanding $ 1,000,000

Additional paid-in capital $ 4,000,000

Retained earnings $ 6,000,000

Total shareholders equity $12,250,000

The following transactions have also occurred at Fitzgerald.

1. Options were granted on July 1, 2013, to purchase 200,000 shares at $15 per share. Although no options were exercised during fiscal year 2014, the average price per common share during fiscal year 2014 was $20 per share.

2. Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2013.

3. The preferred stock was issued in 2013.

4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2014.

5. The 1,000,000 shares of common stock were outstanding for the entire 2014 fiscal year.

6. Net income for fiscal year 2014 was $1,500,000, and the average income tax rate is 40%.

INSTRUCTIONS

For the fiscal year ended June 30, 2014, calculate the following for Fitzgerald Pharmaceutical Industries.

(a) Basic earnings per share.

(b) Diluted earnings per share.